We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CORT's full-year earnings has moved 1.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, CORT has gained about 14.3% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, ANI Pharmaceuticals (ANIP - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.4%.
The consensus estimate for ANI Pharmaceuticals' current year EPS has increased 24% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Corcept Therapeutics belongs to the Medical - Drugs industry, which includes 164 individual stocks and currently sits at #82 in the Zacks Industry Rank. This group has lost an average of 0.8% so far this year, so CORT is performing better in this area.
On the other hand, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #75. The industry has moved +6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Corcept Therapeutics and ANI Pharmaceuticals as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CORT's full-year earnings has moved 1.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, CORT has gained about 14.3% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, ANI Pharmaceuticals (ANIP - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.4%.
The consensus estimate for ANI Pharmaceuticals' current year EPS has increased 24% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Corcept Therapeutics belongs to the Medical - Drugs industry, which includes 164 individual stocks and currently sits at #82 in the Zacks Industry Rank. This group has lost an average of 0.8% so far this year, so CORT is performing better in this area.
On the other hand, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #75. The industry has moved +6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Corcept Therapeutics and ANI Pharmaceuticals as they attempt to continue their solid performance.